MX2017013496A - Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk). - Google Patents

Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk).

Info

Publication number
MX2017013496A
MX2017013496A MX2017013496A MX2017013496A MX2017013496A MX 2017013496 A MX2017013496 A MX 2017013496A MX 2017013496 A MX2017013496 A MX 2017013496A MX 2017013496 A MX2017013496 A MX 2017013496A MX 2017013496 A MX2017013496 A MX 2017013496A
Authority
MX
Mexico
Prior art keywords
host disease
versus host
graft versus
treatment
chronic graft
Prior art date
Application number
MX2017013496A
Other languages
English (en)
Inventor
Haw- Ling Lin Joseph
A Di Paolo Julie
Lee Lin Shao-
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2017013496A publication Critical patent/MX2017013496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción provee métodos para utilizar compuestos inhibidores de Syk en el tratamiento de enfermedad de injerto contra hospedero (GVHD) en un humano, incluyendo enfermedad aguda de injerto contra hospedero (aGVHD) y enfermedad crónica de injerto contra hospedero (cGVHD), incluyendo el uso de compuestos que se seleccionan a partir del grupo que consiste de las siguientes fórmulas: (I) y (II).
MX2017013496A 2015-04-21 2016-04-19 Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk). MX2017013496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150691P 2015-04-21 2015-04-21
PCT/US2016/028303 WO2016172117A1 (en) 2015-04-21 2016-04-19 Treatment of chronic graft versus host disease with syk inhibitors

Publications (1)

Publication Number Publication Date
MX2017013496A true MX2017013496A (es) 2018-02-09

Family

ID=55854820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013496A MX2017013496A (es) 2015-04-21 2016-04-19 Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk).

Country Status (14)

Country Link
US (1) US20160375019A1 (es)
EP (1) EP3285808A1 (es)
JP (1) JP2018513173A (es)
KR (1) KR20170137200A (es)
CN (1) CN107530354A (es)
AU (1) AU2016252387A1 (es)
BR (1) BR112017022323A2 (es)
CA (1) CA2983611A1 (es)
EA (1) EA201791946A1 (es)
HK (2) HK1244453A1 (es)
MX (1) MX2017013496A (es)
SG (1) SG11201708075RA (es)
TW (1) TW201711685A (es)
WO (1) WO2016172117A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2744541T3 (es) 2008-12-08 2020-02-25 Gilead Connecticut Inc Inhibidores de imidazopirazina Syk
JP5938352B2 (ja) 2010-03-11 2016-06-22 ギリアード コネチカット， インコーポレイテッド イミダゾピリジンｓｙｋ阻害剤
MD4659B1 (ro) 2013-07-30 2019-11-30 Gilead Connecticut Inc Polimorf al inhibitorilor SYK
MX2016001427A (es) 2013-07-31 2016-08-03 Gilead Sciences Inc Inhibidores de syk.
CN105764516A (zh) 2013-12-04 2016-07-13 吉利德科学公司 治疗癌症的方法
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
MA40075A (fr) 2014-07-14 2016-01-21 Gilead Sciences Inc Combinaisons pour traiter des cancers
WO2017106564A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
US10111882B2 (en) 2016-09-14 2018-10-30 Gilead Sciences, Inc. SYK inhibitors
JP7179743B2 (ja) * 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗ＳＩＲＰｇ抗体の新規の使用
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
US11746110B2 (en) 2018-07-17 2023-09-05 Shenzhen Targetrx, Inc. Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
CN112939983A (zh) * 2021-02-01 2021-06-11 暨明医药科技（苏州）有限公司 一种SYK激酶抑制剂Lanraplenib的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
DK2716157T3 (en) * 2008-12-08 2016-08-15 Gilead Connecticut Inc Imidazopyrazin-Syk inhibitors
JP6153667B2 (ja) 2013-07-30 2017-06-28 ギリアード コネチカット， インコーポレイテッド Ｓｋｙ阻害剤の製剤
MD4659B1 (ro) 2013-07-30 2019-11-30 Gilead Connecticut Inc Polimorf al inhibitorilor SYK
CN105764516A (zh) * 2013-12-04 2016-07-13 吉利德科学公司 治疗癌症的方法
TWI735853B (zh) * 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

Also Published As

Publication number Publication date
AU2016252387A1 (en) 2017-10-19
CN107530354A (zh) 2018-01-02
SG11201708075RA (en) 2017-11-29
EP3285808A1 (en) 2018-02-28
WO2016172117A1 (en) 2016-10-27
CA2983611A1 (en) 2016-10-27
HK1249054A1 (zh) 2018-10-26
US20160375019A1 (en) 2016-12-29
JP2018513173A (ja) 2018-05-24
BR112017022323A2 (pt) 2018-07-03
HK1244453A1 (zh) 2018-08-10
EA201791946A1 (ru) 2018-03-30
KR20170137200A (ko) 2017-12-12
TW201711685A (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
MX2017013496A (es) Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk).
PH12021550052A1 (en) Methods of treating and preventing graft versus host disease
PH12018502234B1 (en) Treatment of cancer with tor kinase inhibitors
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
MX2021006734A (es) Metodo para tratar el cancer.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
EA201791133A1 (ru) Ингибиторы erk
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2018001737A (es) Mecanismo de resistencia a inhibidores de bromodominio bet.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
WO2015143424A3 (en) Methods of treating cancer
IL280158A (en) Methods of treating cancer with the PI3K inhibitor, GDC-0077
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
MX2016011295A (es) Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2.
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
IL251880A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.